“…The phase 3 HIMALAYA trial showed the superiority of tremelimumab plus durvalumab (STRIDE regimen) [80,81] over sorafenib, and this regimen and durvalumab monotherapy were approved as first-line treatment in Japan in 2023. The STRIDE regimen is inferior to atezolizumab plus bevacizumab in terms of efficacy and safety according to phase 3 data and the recently published 3 network meta-analysis [82][83][84]. Therefore, STRIDE regimen is indicated for patients who are unsuitable for bevacizumab [85][86][87][88] (Fig.…”